RTI Biologics (NAS: RTIX) is expected to report Q4 earnings around Jan. 31. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict RTI Biologics's revenues will increase 5.1% and EPS will drop 0.0%.
The average estimate for revenue is $45.1 million. On the bottom line, the average EPS estimate is $0.04.
Last quarter, RTI Biologics booked revenue of $44.6 million. GAAP reported sales were 5.5% higher than the prior-year quarter's $42.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.05. GAAP EPS of $0.05 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 48.7%, 300 basis points better than the prior-year quarter. Operating margin was 9.2%, 170 basis points better than the prior-year quarter. Net margin was 6.3%, 20 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $178.6 million. The average EPS estimate is $0.18.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 212 members out of 222 rating the stock outperform, and 10 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 50 give RTI Biologics a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on RTI Biologics is outperform, with an average price target of $4.62.
Is RTI Biologics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
Add RTI Biologics to My Watchlist.
The article RTI Biologics Earnings Are on Deck originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.